Refine
Year of publication
Document Type
- Article (73) (remove)
Has Fulltext
- yes (73)
Is part of the Bibliography
- no (73)
Keywords
- COVID-19 (4)
- SARS-CoV-2 (3)
- risk factors (3)
- ACLF (2)
- Biomarkers (2)
- Immunology (2)
- Non-small cell lung cancer (2)
- Portal hypertension (2)
- acute myeloid leukemia (2)
- acute-on-chronic liver failure (2)
- cirrhosis (2)
- inflammation (2)
- portal hypertension (2)
- 32D progenitor cells (1)
- 3years (1)
- ABCB1 (1)
- ABCC1 (1)
- ADGRE1 (1)
- ALK-rearranged NSCLC (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute kidney injury (1)
- Advanced stage (1)
- Alternative oxidase (1)
- Angiogenesis (1)
- Angiography (1)
- Ankylosierende Spondylitis (1)
- Ankylosing spondylitis (1)
- Axial spondyloarthritis (1)
- Axiale Spondyloarthritis (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- BRVO (1)
- Blood (1)
- Blood loss (1)
- Blood plasma (1)
- Brain tumor (1)
- CAKUT (1)
- CBA (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COPD (1)
- COVID (1)
- CV9202 (1)
- CVD biomarker (1)
- Cancer (1)
- Cardiology (1)
- Care gaps (1)
- Cirrhosis (1)
- Clinical trial (1)
- Cohort studies (1)
- Colloids (1)
- Complicated stage (1)
- DME (1)
- Devic disease (1)
- Devic syndrome (1)
- Diabetes (1)
- Drug resistance (1)
- Drug targets (1)
- EMR1 (1)
- EWSR1 (1)
- Emphysema (1)
- Everolimus (1)
- Extended donor criteria (1)
- F4/80 (1)
- FOXO3a (1)
- G3BP (1)
- Gene fusion (1)
- Genetic testing (1)
- Genetics (1)
- Germany (1)
- Graft function (1)
- Graft survival (1)
- HES (1)
- Haematocrit (1)
- Hashimoto’s thyroiditis (1)
- Health care (1)
- Health information (1)
- Health-seeking behaviour (1)
- Heat shock protein 27 (1)
- Helpline (1)
- Hydroxyethyl starch (1)
- Hypofractionated radiotherapy (1)
- IL-6 (1)
- ILUVIEN (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- JAK2V617F (1)
- K3EDTA plasma sampling (1)
- Kidney transplantation (1)
- LEOSS (1)
- Lipidomics (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Ltbp4 (1)
- MCP (1)
- MN1 (1)
- MR-proADM (1)
- Machine learning (1)
- Marginal grafts (1)
- Mean erythrocyte volume (1)
- Medication Appropriateness Index (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metabolomics (1)
- Mitochondria (1)
- Mitochondrial disease (1)
- Molecular diagnostic testing (1)
- Molecular medicine (1)
- Mortality (1)
- NAFL (1)
- NAFLD (1)
- NASH (1)
- NMO-IgG (1)
- Nephrons (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Nrf2 (1)
- Number of platelets (1)
- Oncology (1)
- Organ rinse (1)
- Organ shortage (1)
- PATZ1 (1)
- PTDM (1)
- Pdgfrβ (1)
- Pediatric (1)
- Periodontitis grades B and C (1)
- Polo-like kinase 3 (1)
- Portal veins (1)
- Post-transplant (1)
- Pre-analytics (1)
- Predictive model (1)
- Primary prophylaxis (1)
- Proteins (1)
- Psychiatric disorders (1)
- Quality of care (1)
- Quality standards (1)
- Qualitätsstandards (1)
- ROS (1)
- Radical nephrectomy (1)
- Rare diseases (1)
- Registries (1)
- Renal cancer (1)
- Renal system (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Rho GTPases (1)
- SD-OCT (1)
- SLC20A1 (1)
- SOFA (1)
- SPSS (1)
- Sampling protocol (1)
- Sepsis (1)
- Septic shock (1)
- Spontaneous bacterial peritonitis (1)
- Steroid (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- TGR(mREN2)27 (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Tacrolimus (1)
- Telemedicine (1)
- Tgfβ (1)
- Trauma (1)
- VEGF (1)
- Versorgungslücken (1)
- Versorgungsqualität (1)
- Volume therapy (1)
- Western diet (1)
- White blood cells (1)
- YM155 (1)
- accident (1)
- acute decompensation (1)
- acute-on-chronic liver failure (ACLF) (1)
- adhesion (1)
- advanced care planning (1)
- aftercare structures (1)
- aging (1)
- anal carcinoma (1)
- anticonvulsants (1)
- aquaporin-4 (AQP4) antibody (1)
- bladder exstrophy-epispadias complex (1)
- bleeding (1)
- cancer (1)
- caspase-8 (1)
- cerebrospinal fluid (1)
- chemoradiotherapy (1)
- chronic kidney disease (1)
- chronic myeloid leukemia (1)
- clinical features (1)
- cloacal malformation (1)
- comorbidities (1)
- computed tomography (1)
- computer-assisted drug therapy (1)
- consensus (1)
- critically ill patients (1)
- cytarabine dose (1)
- day clinic (1)
- decompensated liver cirrhosis (1)
- differentiated thyroid carcinoma (1)
- drug resistance (1)
- dysbiosis (1)
- elderly (1)
- epidemiology (1)
- epilepsy (1)
- epileptic encephalopathies (1)
- essential thrombocythemia (ET) (1)
- functional genetics (1)
- glycobiology (1)
- glycoconjugate (1)
- health information exchange (1)
- hepatic encephalopathy (1)
- homing (1)
- hospital admission (1)
- immunity (1)
- infectious disease (1)
- injury (1)
- kidney formation (1)
- lasso regression (1)
- lethal toxin (1)
- levetiracetam (1)
- liver (1)
- liver fibrosis (1)
- liver transplantation (1)
- liver transplantation center (1)
- local control (1)
- lockdown (1)
- long-term outcome (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- macrophage (1)
- magnetic resonance imaging (1)
- male (1)
- mechanical ventilation (1)
- medication reconciliation (1)
- metabolic reprogramming (1)
- metabolic syndromes (1)
- microbiome (1)
- microdosing (1)
- migration (1)
- molecular modeling (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mortality (1)
- multimodal complex treatment (1)
- multimorbidity (1)
- multiple chronic conditions (1)
- myeloproliferative neoplasms (MPN) (1)
- networks (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological manifestations (1)
- neutralizing antibodies (1)
- nomogram (1)
- pediatric intensive care (1)
- peri-implantitis (1)
- polycythemia vera (PV) (1)
- polypharmacy (1)
- portosystemic shunt (1)
- post-liver transplantation management (1)
- primary myelofibrosis (PMF) (1)
- proteomics (1)
- pulmonary failure (1)
- qualitative research (1)
- quality control (1)
- rare diseases (1)
- recurrent optic neuritis (1)
- renal dysfunction (1)
- respiratory failure (1)
- retrovirus (1)
- risk factor progression (1)
- risk stratification (1)
- seizure (1)
- sequential ALK-inhibitor therapy (1)
- sialic acid (1)
- sirtuin1 (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- survival (1)
- survivin (1)
- thromboembolism (1)
- thrombosis (1)
- toxin B (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- trauma (1)
- tyrosine kinase inhibitors. (1)
- urinary tract development (1)
- variants of concern (1)
- vitamin D (1)
- vitamin D receptor (1)
- vitreous samples (1)
- zebrafish development (1)
Institute
- Medizin (73) (remove)
Background The differential diagnosis between follicular thyroid adenoma and minimal invasive follicular thyroid carcinoma is often difficult for several reasons. One major aspect is the lack of typical cytological criteria in well differentiated specimens. New marker molecules, shown by poly- or monoclonal antibodies proved helpful. Methods We performed global gene expression analysis of 12 follicular thyroid tumours (4 follicular adenomas, 4 minimal invasive follicular carcinomas and 4 widely invasive follicular carcinomas), followed by immunohistochemical staining of 149 cases. The specificity of the antibody was validated by western blot analysis Results In gene expression analysis QPRT was detected as differently expressed between follicular thyroid adenoma and follicular thyroid carcinoma. QPRT protein could be detected by immunohistochemistry in 65% of follicular thyroid carcinomas including minimal invasive variant and only 22% of follicular adenomas. Conclusion Consequently, QPRT is a potential new marker for the immunohistochemical screening of follicular thyroid nodules.
Background: Hypothermia has been discussed as playing a role in improving the early phase of systemic inflammation. However, information on the impact of hypothermia on the local inflammatory response is sparse. We therefore investigated the kinetics of local and systemic inflammation in the late posttraumatic phase after induction of hypothermia in an established porcine long-term model of combined trauma.
Materials & Methods: Male pigs (35 ± 5kg) were mechanically ventilated and monitored over the study period of 48 h. Combined trauma included tibia fracture, lung contusion, liver laceration and pressure-controlled hemorrhagic shock (MAP < 30 ± 5 mmHg for 90 min). After resuscitation, hypothermia (33°C) was induced for a period of 12 h (HT-T group) with subsequent re-warming over a period of 10 h. The NT-T group was kept normothermic. Systemic and local (fracture hematoma) cytokine levels (IL-6, -8, -10) and alarmins (HMGB1, HSP70) were measured via ELISA.
Results: Severe signs of shock as well as systemic and local increases of pro-inflammatory mediators were observed in both trauma groups. In general the local increase of pro- and anti-inflammatory mediator levels was significantly higher and prolonged compared to systemic concentrations. Induction of hypothermia resulted in a significantly prolonged elevation of both systemic and local HMGB1 levels at 48 h compared to the NT-T group. Correspondingly, local IL-6 levels demonstrated a significantly prolonged increase in the HT-T group at 48 h.
Conclusion: A prolonged inflammatory response might reduce the well-described protective effects on organ and immune function observed in the early phase after hypothermia induction. Furthermore, local immune response also seems to be affected. Future studies should aim to investigate the use of therapeutic hypothermia at different degrees and duration of application.
Background and Aim: Several studies observed alterations in the gut microbiota in patients with non‐alcoholic fatty liver disease (NAFLD). However, analyzed patient populations and methods strongly differ among these studies. The aim of this study was to prove the reproducibility of published results and to provide a detailed overview of all findings in our NAFLD cohort using next generation sequencing methods.
Methods: The individual taxonomic microbiota composition of fecal samples from 90 NAFLD patients and 21 healthy controls was analyzed using 16S rRNA gene sequencing. Study participants were grouped according to their disease stage and compared regarding their gut microbiota composition. Studies were identified from PubMed listed publications, and the results were compared with the findings in our cohort.
Results: Results from 13 identified studies were compared with our data. A decreased abundance of the Bacteroidetes and Ruminococcaceae as well as an increased abundance of Lactobacillaceae and Veillonellaceae and Dorea were the most frequently reported changes among NAFLD patients in 4/13, 5/13, 4/13, 2/13, and 3/13 studies, respectively. Even though these alterations in the gut microbiota composition were also observed in our patient cohort, the majority of published differences could not be reproduced, neither in our own nor in other NAFLD cohort studies.
Conclusion: Despite repeatedly reproduced abundance patterns of specific bacteria, the heterogeneous study results did not reveal a consistent disease specific gut microbiota signature. Further prospective studies with homogenous patient cohorts and standardized methods are necessary to phenotype NAFLD by the gut microbiota.
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE).
Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.
Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%.
Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.
Background: Protective effects of vitamin D have been reported in autoimmune and malignant thyroid diseases, though little is known about the underlying mechanism. Sirtuin 1 histon deacethylase (SIRT1) links the vitamin D pathway with regulation of transcription factor FOXO3a, a key player in cell cycle regulation and apoptosis. Aim of the present study was to investigate common single nucleotide polymorphisms (SNP's) in FOXO3a gene in respect to thyroid diseases, as well as to evaluate the hypothesis of Sirtuin1-FOXO3a interaction being a mediator of anti-proliferative vitamin D effects.
Methods: The SNP's FOXO3a rs4946936/rs4945816/rs9400239 were genotyped in 257 patients with differentiated thyroid carcinoma (DTC), 139 patients with Hashimoto thyroiditis (HT) and 463 healthy controls (HC). Moreover, T-helper cells of HC and papillary thyroid cancer cell line BCPAP were incubated with 1,25(OH)2D3 and/or SIRT1 inhibitor Ex-527 in order to elucidate SIRT1- dependent vitamin D effects on cell proliferation and FOXO3a gene expression in vitro.
Results: Patients with DTC tended to carry more often allele C in FOXO3a rs4946936 in comparison to HC (pcorrected = pc = 0.08). FOXO3a rs9400239T and rs4945816C was more frequent in HT in comparison to HC (pc = 0.02 and pc = 0.01, respectively). In both DTC and HT, we could not find a correlation of FOXO3a SNP's with vitamin D status. However, on in vitro level, 1,25(OH)2D3 showed an anti-proliferative effect in both T-helper cells and BCPAP, that was blocked by SIRT1 inhibition (T-helper cells: p = 0.0059, BCPAP: p = 0.04) and accompanied by elevated FOXO3a gene expression in T-helper cells (p = 0.05).
Conclusions: FOXO3a rs9400239T and rs4945816C may constitute risk factors for HT, independent of the vitamin D status.This indicates the implication of FOXO3a in pathogenesis of autoimmune thyroid diseases. The dependency of anti-proliferative vitamin D effects on SIRT1 activity further suggests a key role of vitamin D-SIRT1-FOXO3a axis for protective vitamin D effects.
Background: Pathogenesis of portal hypertension is multifactorial and includes pathologic intrahepatic angiogenesis, whereby TIPS insertion is an effective therapy of portal hypertension associated complications. While angiogenin is a potent contributor to angiogenesis in general, little is known about its impact on TIPS function over time. Methods: In a total of 118 samples from 47 patients, angiogenin concentrations were measured in portal and inferior caval vein plasma at TIPS insertion (each blood compartment n = 23) or angiographic intervention after TIPS (each blood compartment n = 36) and its relationship with patient outcome was investigated. Results: Angiogenin levels in the inferior caval vein were significantly higher compared to the portal vein (P = 0.048). Ten to 14 days after TIPS, inferior caval vein angiogenin level correlated inversely with the portal systemic pressure gradient (P<0.001), measured invasively during control angiography. Moreover, patients with TIPS revision during this angiography, showed significantly lower angiogenin level in the inferior caval vein compared to patients without TIPS dysfunction (P = 0.01). Conclusion: In cirrhosis patients with complications of severe portal hypertension, circulating levels of angiogenin are derived from the injured liver. Moreover, angiogenin levels in the inferior caval vein after TIPS may predict TIPS dysfunction.
Background & Aims: Spontaneous portosystemic shunts (SPSS) frequently develop in liver cirrhosis. Recent data suggested that the presence of a single large SPSS is associated with complications, especially overt hepatic encephalopathy (oHE). However, the presence of >1 SPSS is common. This study evaluates the impact of total cross-sectional SPSS area (TSA) on outcomes in patients with liver cirrhosis.
Methods: In this retrospective international multicentric study, CT scans of 908 cirrhotic patients with SPSS were evaluated for TSA. Clinical and laboratory data were recorded. Each detected SPSS radius was measured and TSA calculated. One-year survival was the primary endpoint and acute decompensation (oHE, variceal bleeding, ascites) was the secondary endpoint.
Results: A total of 301 patients (169 male) were included in the training cohort. Thirty percent of all patients presented with >1 SPSS. A TSA cut-off of 83 mm2 was used to classify patients with small or large TSA (S-/L-TSA). Patients with L-TSA presented with higher model for end-stage liver disease score (11 vs. 14) and more commonly had a history of oHE (12% vs. 21%, p <0.05). During follow-up, patients with L-TSA experienced more oHE episodes (33% vs. 47%, p <0.05) and had lower 1-year survival than those with S-TSA (84% vs. 69%, p <0.001). Multivariate analysis identified L-TSA (hazard ratio 1.66; 95% CI 1.02–2.70, p <0.05) as an independent predictor of mortality. An independent multicentric validation cohort of 607 patients confirmed that patients with L-TSA had lower 1-year survival (77% vs. 64%, p <0.001) and more oHE development (35% vs. 49%, p <0.001) than those with S-TSA.
Conclusion: This study suggests that TSA >83 mm2 increases the risk for oHE and mortality in patients with cirrhosis. Our results support the clinical use of TSA/SPSS for risk stratification and decision-making in the management of patients with cirrhosis.
Lay summary: The prevalence of spontaneous portosystemic shunts (SPSS) is higher in patients with more advanced chronic liver disease. The presence of more than 1 SPSS is common in advanced chronic liver disease and is associated with the development of hepatic encephalopathy. This study shows that total cross-sectional SPSS area (rather than diameter of the single largest SPSS) predicts survival in patients with advanced chronic liver disease. Our results support the clinical use of total cross-sectional SPSS area for risk stratification and decision-making in the management of SPSS.
Background and Objectives: Proteins of the coagulation system contribute to autoimmune inflammation in patients with multiple sclerosis (MS). On blood-brain barrier (BBB) disruption, fibrinogen enters the CNS and is rapidly converted to fibrin, unfolding pleiotropic autoimmune mechanisms. Fibrin accumulation leads to subsequent proteolytic degradation that results in D-dimer generation. The primary objective of this study was to determine intrathecal levels of D-dimer in CSF as a measure of intrathecal coagulation cascade activation and to evaluate its diagnostic utility in patients with MS in contrast to healthy subjects. Key secondary objectives included analysis of CSF D-dimer in differential diagnoses of MS and its relation to routine clinical markers of disease activity.
Methods: Patients admitted for the assessment of suspected MS were prospectively recruited from October 2017 to December 2020. Blood plasma and citrated CSF samples were analyzed using a highly sensitive luminescent oxygen channeling immunoassay. Intrathecal generation of D-dimer was analyzed by adjusting for CSF/serum albumin (Qalb) and CSF/plasma D-dimer quotients (QD-dimer), and corresponding CSF fibrinogen levels were determined. Final diagnoses after full evaluation and clinical data were recorded.
Results: Of 187 patients, 113 patients received a diagnosis of MS or clinically/radiologically isolated syndrome. We found increased intrathecal CSF D-dimer generation levels (QD-dimer/Qalb-index) for patients with relapsing-remitting MS (RRMS; n = 71, median 4.7, interquartile range [IQR] 2.5–8.0) when compared with those for disease controls (n = 22, median 2.6, IQR 2.1–4.8, p = 0.031). Absolute CSF D-dimer values correlated with CSF fibrinogen levels (r = 0.463; p < 0 .001) and CSF leukocytes (r = 0.273; p = 0.003) and were elevated in MS patients with contrast enhancement (CE) compared with MS patients without CE on MRI (n = 48, median 6 ng/mL, and IQR 3–15.25 vs n = 41, median 4 ng/mL, and IQR 2–7; p = 0.026). Exploratory subgroup analyses indicated a correlation of intrathecal inflammatory activity and CSF D-dimer levels.
Discussion: D-dimer in CSF can be reliably determined and correlates with markers of CNS inflammation and CSF fibrinogen levels. Adjusted for BBB dysfunction, CSF D-dimer may allow the identification of intrathecal coagulation cascade activation in patients with MS.
Classification of Evidence: This study provides Class I evidence that CSF D-dimer levels are elevated in patients with RRMS.
Siglec-1 (sialoadhesin, CD169) is a surface receptor on human cells that mediates trans-enhancement of HIV-1 infection through recognition of sialic acid moieties in virus membrane gangliosides. Here, we demonstrate that mouse Siglec-1, expressed on the surface of primary macrophages in an interferon-α-responsive manner, captures murine leukemia virus (MLV) particles and mediates their transfer to proliferating lymphocytes. The MLV infection of primary B-cells was markedly more efficient than that of primary T-cells. The major structural protein of MLV particles, Gag, frequently co-localized with Siglec-1, and trans-infection, primarily of surface-bound MLV particles, efficiently occurred. To explore the role of sialic acid for MLV trans-infection at a submolecular level, we analyzed the potential of six sialic acid precursor analogs to modulate the sialylated ganglioside-dependent interaction of MLV particles with Siglec-1. Biosynthetically engineered sialic acids were detected in both the glycolipid and glycoprotein fractions of MLV producer cells. MLV released from cells carrying N-acyl-modified sialic acids displayed strikingly different capacities for Siglec-1-mediated capture and trans-infection; N-butanoyl, N-isobutanoyl, N-glycolyl, or N-pentanoyl side chain modifications resulted in up to 92 and 80% reduction of virus particle capture and trans-infection, respectively, whereas N-propanoyl or N-cyclopropylcarbamyl side chains had no effect. In agreement with these functional analyses, molecular modeling indicated reduced binding affinities for non-functional N-acyl modifications. Thus, Siglec-1 is a key receptor for macrophage/lymphocyte trans-infection of surface-bound virions, and the N-acyl side chain of sialic acid is a critical determinant for the Siglec-1/MLV interaction.
The development of resistance to chemotherapeutic agents, such as Doxorubicin (DOX) and cytarabine (AraC), is one of the greatest challenges to the successful treatment of Acute Myeloid Leukemia (AML). Such acquisition is often underlined by a metabolic reprogramming that can provide a therapeutic opportunity, as it can lead to the emergence of vulnerabilities and dependencies to be exploited as targets against the resistant cells. In this regard, genome-scale metabolic models (GSMMs) have emerged as powerful tools to integrate multiple layers of data to build cancer-specific models and identify putative metabolic vulnerabilities. Here, we use genome-scale metabolic modelling to reconstruct a GSMM of the THP1 AML cell line and two derivative cell lines, one with acquired resistance to AraC and the second with acquired resistance to DOX. We also explore how, adding to the transcriptomic layer, the metabolomic layer enhances the selectivity of the resulting condition specific reconstructions. The resulting models enabled us to identify and experimentally validate that drug-resistant THP1 cells are sensitive to the FDA-approved antifolate methotrexate. Moreover, we discovered and validated that the resistant cell lines could be selectively targeted by inhibiting squalene synthase, providing a new and promising strategy to directly inhibit cholesterol synthesis in AML drug resistant cells.